tetano
Editor, Senior Moderator
Curr Probl Cardiol
. 2023 Jul 7;101933.
doi: 10.1016/j.cpcardiol.2023.101933. Online ahead of print. COVID-19 Patients with Pulmonary Hypertension Hospitalized in the United States During the Early Pandemic: Analysis of In-Hospital Mortality, Clinical Outcomes, and Racial Disparities
Harris Majeed[SUP] 1 [/SUP], Bobby Cannon[SUP] 2 [/SUP], Kavin Raj[SUP] 3 [/SUP], Adeel Nasrullah[SUP] 4 [/SUP], Safwan Majeed[SUP] 5 [/SUP], Karthick Gangu[SUP] 6 [/SUP], Asif Farooq[SUP] 7 [/SUP], Abu Baker Sheikh[SUP] 2 [/SUP]
Affiliations
Coronavirus Disease 2019 (COVID-19) has been linked to severe consequences among hospitalized patients diagnosed with pulmonary hypertension (PH), as evidenced by a limited number of studies. Our retrospective study employed the National Inpatient Sample (NIS) database to evaluate in-hospital mortality and various clinical outcomes in COVID-19 patients with and without PH. This study included all patients ages 18 years and above who were hospitalized in the United States from January 1,2020 to December 31, 2020 with a COVID-19 diagnosis. The patients were then divided into two cohorts based on their PH status. After multivariate adjustment, we discovered that COVID-19 patients with PH experienced considerably higher in-hospital mortality, longer hospital stays, and higher costs of hospitalization when compared to COVID-19 patients without PH. Moreover, we observed an increased dependence on invasive and non-invasive positive pressure ventilation among COVID-19 patients with PH, indicating more severe respiratory failure. Our findings suggest that COVID-19 patients with PH had a heightened risk of acute pulmonary embolism and myocardial infarction while hospitalized. Lastly, among COVID-19 patients with PH, Hispanic and Native American patients demonstrated a persistently higher risk of in-hospital mortality compared to other racial groups. To our knowledge, this is the most comprehensive study of outcomes for COVID-19 patients with PH. The observed inpatient mortality appears to be driven by in-hospital complications, particularly pulmonary embolism. Given the substantial mortality and complications associated with COVID-19 and PH, we advocate for SARS-CoV-2 vaccination and the implementation of aggressive non-pharmacological preventive measures.
. 2023 Jul 7;101933.
doi: 10.1016/j.cpcardiol.2023.101933. Online ahead of print. COVID-19 Patients with Pulmonary Hypertension Hospitalized in the United States During the Early Pandemic: Analysis of In-Hospital Mortality, Clinical Outcomes, and Racial Disparities
Harris Majeed[SUP] 1 [/SUP], Bobby Cannon[SUP] 2 [/SUP], Kavin Raj[SUP] 3 [/SUP], Adeel Nasrullah[SUP] 4 [/SUP], Safwan Majeed[SUP] 5 [/SUP], Karthick Gangu[SUP] 6 [/SUP], Asif Farooq[SUP] 7 [/SUP], Abu Baker Sheikh[SUP] 2 [/SUP]
Affiliations
- PMID: 37422043
- DOI: 10.1016/j.cpcardiol.2023.101933
Coronavirus Disease 2019 (COVID-19) has been linked to severe consequences among hospitalized patients diagnosed with pulmonary hypertension (PH), as evidenced by a limited number of studies. Our retrospective study employed the National Inpatient Sample (NIS) database to evaluate in-hospital mortality and various clinical outcomes in COVID-19 patients with and without PH. This study included all patients ages 18 years and above who were hospitalized in the United States from January 1,2020 to December 31, 2020 with a COVID-19 diagnosis. The patients were then divided into two cohorts based on their PH status. After multivariate adjustment, we discovered that COVID-19 patients with PH experienced considerably higher in-hospital mortality, longer hospital stays, and higher costs of hospitalization when compared to COVID-19 patients without PH. Moreover, we observed an increased dependence on invasive and non-invasive positive pressure ventilation among COVID-19 patients with PH, indicating more severe respiratory failure. Our findings suggest that COVID-19 patients with PH had a heightened risk of acute pulmonary embolism and myocardial infarction while hospitalized. Lastly, among COVID-19 patients with PH, Hispanic and Native American patients demonstrated a persistently higher risk of in-hospital mortality compared to other racial groups. To our knowledge, this is the most comprehensive study of outcomes for COVID-19 patients with PH. The observed inpatient mortality appears to be driven by in-hospital complications, particularly pulmonary embolism. Given the substantial mortality and complications associated with COVID-19 and PH, we advocate for SARS-CoV-2 vaccination and the implementation of aggressive non-pharmacological preventive measures.